KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Acquisitions & Divestments (2016 - 2026)

Alnylam Pharmaceuticals filings provide 18 years of Change in Acquisitions & Divestments readings, the most recent being $213.2 million for Q1 2026.

  • Quarterly Change in Acquisitions & Divestments rose 336.64% to $213.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.0 billion through Mar 2026, up 24.43% year-over-year, with the annual reading at $1.8 billion for FY2025, 14.67% up from the prior year.
  • Change in Acquisitions & Divestments hit $213.2 million in Q1 2026 for Alnylam Pharmaceuticals, down from $1.7 billion in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $1.7 billion in Q4 2025 and bottomed at -$797.1 million in Q3 2025.
  • Average Change in Acquisitions & Divestments over 5 years is $460.8 million, with a median of $293.3 million recorded in 2023.
  • Peak annual rise in Change in Acquisitions & Divestments hit 3872.55% in 2023, while the deepest fall reached 2224.42% in 2023.
  • Alnylam Pharmaceuticals' Change in Acquisitions & Divestments stood at $604.7 million in 2022, then surged by 147.28% to $1.5 billion in 2023, then grew by 1.23% to $1.5 billion in 2024, then increased by 15.11% to $1.7 billion in 2025, then tumbled by 87.77% to $213.2 million in 2026.
  • Per Business Quant, the three most recent readings for ALNY's Change in Acquisitions & Divestments are $213.2 million (Q1 2026), $1.7 billion (Q4 2025), and -$797.1 million (Q3 2025).